Form 8-K - Current report:
SEC Accession No. 0001082554-26-000021
Filing Date
2026-05-06
Accepted
2026-05-06 06:31:29
Documents
13
Period of Report
2026-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K uthr-20260506.htm   iXBRL 8-K 29563
2 EX-99.1 uthrq12026-ex991.htm EX-99.1 248688
6 GRAPHIC ut_lungiconxredxlogo.jpg GRAPHIC 13650
  Complete submission text file 0001082554-26-000021.txt   428494

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT uthr-20260506.xsd EX-101.SCH 1820
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT uthr-20260506_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT uthr-20260506_pre.xml EX-101.PRE 12544
16 EXTRACTED XBRL INSTANCE DOCUMENT uthr-20260506_htm.xml XML 2728
Mailing Address 1000 SPRING ST SILVER SPRING MD 20910
Business Address 1000 SPRING ST SILVER SPRING MD 20910 3016089292
UNITED THERAPEUTICS Corp (Filer) CIK: 0001082554 (see all company filings)

EIN.: 521984749 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26301 | Film No.: 26945685
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)